Company intelligence / Profile preview
AGIRx Ltd.
- Ownership
- Private
- Development stage
- Other
01
Overview
AGIRx conducted a Phase 1/2 clinical trial (NCT00716495) for AGI-101H in advanced melanoma patients. The trial was terminated. The drug was a whole cell, allogeneic melanoma vaccine representing a mixture of two therapeutic gene modified human melanoma cell lines (Mich1H6 and Mich2H6) in a 1:1 ratio.
- Therapeutic areas
- Oncology
- Modalities
- Whole cell allogeneic vaccine
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on AGIRx Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGIRx Ltd..